Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RJVA-001 first-in-human trial in adults with inadequately controlled type 2 diabetes
NL-OMON61067Phase 2Not yet recruiting
- Sponsor
- Fractyl Health
- Start
- Sep 2026
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of RJVA-001 in type 2 diabetes mellitus (T2DM), sponsored by Fractyl Health. Primary endpoint: Safety and tolerability. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
RJVA-001
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON61067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61067.